Identification of Pharmacological Chaperones for Gaucher Disease and Characterization of Their Effects on β‐Glucocerebrosidase by Hydrogen/Deuterium Exchange Mass Spectrometry
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Point mutations in β‐glucocerebrosidase (GCase) can result in a deficiency of both GCase activity and protein in lysosomes thereby causing Gaucher Disease (GD). Enzyme inhibitors such as isofagomine, acting as pharmacological chaperones (PCs), increase these levels by binding and stabilizing the native form of the enzyme in the endoplasmic reticulum (ER), and allow increased lysosomal transport of the enzyme. A high‐throughput screen of the 50 000‐compound Maybridge library identified two, non‐carbohydrate‐based inhibitory molecules, a 2,4‐diamino‐5‐substituted quinazoline (IC 50 5 μ M) and a 5‐substituted pyridinyl‐2‐furamide (IC 50 8 μ M). They raised the levels of functional GCase 1.5–2.5‐fold in N370S or F213I GD fibroblasts. Immunofluorescence confirmed that treated GD fibroblasts had decreased levels of GCase in their ER and increased levels in lysosomes. Changes in protein dynamics, monitored by hydrogen/deuterium‐exchange mass spectrometry, identified a domain III active‐site loop (residues 243–249) as being significantly stabilized upon binding of isofagomine or either of these two new compounds; this suggests a common mechanism for PC enhancement of intracellular transport.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
Yoshida, H. (2007) · The FEBS Journal · doi:10.1111/j.1742-4658.2007.05639.x · Cited by 1,086
Autophagy Controls Salmonella Infection in Response to Damage to the Salmonella-containing Vacuole
Birmingham, C. L., Smith, A. C., Bakowski, M. A., Yoshimori, T., & Brumell, J. H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m509157200 · Cited by 658
Tropak, M. B., Blanchard, J. E., Withers, S. G., Brown, E. D., & Mahuran, D. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.12.006 · Cited by 105
Self-citation
Cited by
Glycosylation in health and disease
Reily, C., Stewart, T. J., Renfrow, M. B., & Novak, J. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0129-4 · Cited by 2,075
Identification and Characterization of Ambroxol as an Enzyme Enhancement Agent for Gaucher Disease
Maegawa, G. H. B., Tropak, M. B., Buttner, J. D., Rigat, B. A., Fuller, M., Pandit, D., Tang, L., Kornhaber, G. J., Hamuro, Y., Clarke, J. T. R., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.012393 · Cited by 332
Self-citationTreating lysosomal storage diseases with pharmacological chaperones: from concept to clinics
Parenti, G. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900036 · Cited by 273
Pharmacological Chaperones as Therapeutics for Lysosomal Storage Diseases
Boyd, R. E., Lee, G., Rybczynski, P., Benjamin, E. R., Khanna, R., Wustman, B. A., & Valenzano, K. J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301557k · Cited by 209
Convertino, M., Das, J., & Dokholyan, N. V. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00195 · Cited by 105
Panicker, L. M., Miller, D., Awad, O., Bose, V., Lun, Y., Park, T. S., Zambidis, E. T., Sgambato, J. A., & Feldman, R. A. (2014) · Stem Cells · doi:10.1002/stem.1732 · Cited by 92
Second-Generation Pharmacological Chaperones: Beyond Inhibitors
Tran, M. L., Génisson, Y., Ballereau, S., & Dehoux, C. (2020) · Molecules · doi:10.3390/molecules25143145 · Cited by 63
Bahr, B. A., Wisniewski, M. L., & Butler, D. (2012) · Rejuvenation Research · doi:10.1089/rej.2011.1282 · Cited by 42
Metadata
- Authors
- Tropak, M. B., Kornhaber, G. J., Rigat, B. A., Maegawa, G. H., Buttner, J. D., Blanchard, J. E., Murphy, C., Tuske, S. J., Coales, S. J., Hamuro, Y., Brown, E. D., & Mahuran, D. J.
- Venue
- ChemBioChem
- Publisher
- Wiley
- Published
- 2008-10-29
- Volume
- 9
- Issue
- 16
- Pages
- 2650-2662
- ISSN
- 1439-4227 (ISSN-L)
- 1439-7633
- OpenAlex
- W2116563547
- Cited by
- 75
- References
- 4
- FWCI
- 6.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.